Physician profile
James V Ortman
NPI 1154423085
$1,717.48
in general payments reported to CMS, 2019-2025
27 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $120 · 2021: $164 · 2022: $148 · 2023: $315 · 2024: $365 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $859.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $858.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $230.48 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $215.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $175.36 | 2019-2024 | |
| Amgen INC. | $175.29 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $156.66 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $108.97 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $83.61 | 2023-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $79.76 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $61.68 | 2023-2024 | Rexulti |
| Sumitomo Pharma America, INC. | $57.60 | 2023-2024 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.99 | 2024 | Xifaxan |
| Inspire Medical Systems, INC. | $37.65 | 2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $35.25 | 2023 | |
| Astellas Pharma US INC | $30.96 | 2019 | |
| Merck Sharp & Dohme LLC | $27.41 | 2022-2023 | Belsomra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $24.53 | 2024 | Opsumit, Uptravi |
| Amphastar Pharmaceuticals, INC. | $24.11 | 2025 | |
| Abbott Laboratories | $21.47 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.27 | 2023 | |
| Esperion Therapeutics, INC. | $18.67 | 2022 | |
| Biogen, INC. | $17.34 | 2021 | |
| Exact Sciences Corporation | $16.23 | 2025 | Cologuard Collection Kit |
| Shire North American Group INC | $13.51 | 2019 | |
| Eisai INC. | $12.55 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.38 | 2025 | Voquezna |
| Janssen Pharmaceuticals, INC | $12.03 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ortman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.